Disruption of embryonic vascular development in predictive toxicology

Birth Defects Research Part C - Embryo Today: Reviews

Volumn 93, Issue 4, 2011, Pages 312-323

  Knudsen, Thomas B ^a   Kleinstreuer, Nicole C ^a  

^a U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

Author keywords

Adverse outcome pathway; Angiogenesis; Developmental toxicity; Predictive toxicology; Vascular development

Indexed keywords

CHEMOKINE; CIGARETTE SMOKE; DIOXIN; ENDOTHELIN; ESTRADIOL; ESTROGEN; G PROTEIN COUPLED RECEPTOR; METAL; PLASMINOGEN ACTIVATOR; PLATELET DERIVED GROWTH FACTOR B; RETINOID; THALIDOMIDE; TRANSFORMING GROWTH FACTOR BETA; VASCULAR TARGETING AGENT; VASCULOTROPIN A;

ADVERSE OUTCOME; ANGIOGENESIS; ANGIOOSTEOHYPERTROPHY SYNDROME; CELL FUNCTION; CYTOTOXICITY; EMBRYO DEVELOPMENT; EMBRYO MEMBRANE; FETUS MALFORMATION; GENE DISRUPTION; GENETICS; HUMAN; MOLECULARLY TARGETED THERAPY; NONHUMAN; PREDICTIVE TOXICOLOGY; PREGNANCY; PRENATAL DEVELOPMENT; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; TOXICITY TESTING; TOXICOLOGY;

ANIMALS; CARDIOVASCULAR SYSTEM; EMBRYONIC DEVELOPMENT; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MICE; RATS; RISK ASSESSMENT; TERATOGENS; TOXICITY TESTS;

EID: 84856241088     PISSN: 1542975X     EISSN: 15429768     Source Type: Journal    
DOI: 10.1002/bdrc.20223     Document Type: Review

References (77)

1. Abbott BD and Buckalew AR. 2000. Placental defects in ARNT-knockout conceptus correlate with localized decreases in VEGF-R2, Ang-1, and Tie-2. Devel Dyn 219: 526-538.
2. Ambler CA, Nowicki JL, Burke AC and Bautch V. (2001). Assembly of trunk and limb blood vessels involves extensive migration and vasculogenesis of somite-derived angioblasts. Dev Biol 234: 352-364.
3. Ankley GT, Bennett RS, Erickson RJ, et al. 2010. Adverse outcome pathway: A conceptual framework to support ecotoxicology and risk assessment. Environ Toxicol Chem 29: 730-741.
4. Bosquiazzo VL, Varayoud J, Muñoz-de-Toro M, et al. 2010. Effects of neonatal exposure to bisphenol a on steroid regulation of vascular endothelial growth factor expression and endothelial cell proliferation in the adult rat uterus. Biol Reprod 82: 86-95.
5. Boyd NL, Nunes SS, Jokinen JD, et al. 2011. Microvascular mural cell functionality of human embryonic stem cell-derived mesenchymal cells. Tissue Eng Part A 17: 1537-1548.
6. Bredhult C, Bäcklin B-M, Olovsson M. 2007. Effects of some endocrine disruptors on the proliferation and viability of human endometrial endothelial cells in vitro. Reprod Toxicol 23: 550-559.
7. Brouillard PVikkula M. 2007. Genetic causes of vascular malformations. Hum Mol Genet 16 Spec No. 2: R140-R149.
8. Carney EW, Tornesi B, Keller C, et al. 2007. Refinement of a morphological scoring system for postimplantation rabbit conceptuses. Birth Defects Res B 80: 213-222.
9. Cha YR, Weinstein BM. 2007. Visualization and experimental analysis of blood vessel formation using transgenic zebrafish. Birth Defects Res C 81: 286-296.
10. Chung AS, Ferrara N. 2011. Developmental and pathological angiogenesis. Ann Rev Cell Dev Biol 27: 563-584.
11. Collins FS, Gray GM, Bucher JR. 2008. Transforming environmental health protection. Science 319: 906-907.
12. Coultas L, Chawengsaksophak K, Rossant J. 2005. Endothelial cells and VEGF in vascular development. Nature 438: 937-945.
13. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. 1994. Thalidomide is an inhibitor of angiogenesis. Proc Nat Acad Sci U S A 91: 4082-4085.
14. Dix DJ, Houck KA, Martin MT, et al. 2007. The ToxCast program for prioritizing toxicity testing of environmental chemicals. Toxicol Sci 95: 5-12.
15. Drake CJ, Fleming PA, Argraves WS. 2007. The genetics of vasculogenesis. In: Chadwick DJ, Goode J, editors. Vascular development. Hoboken: Wiley. pp. 61-70.
16. Dumont DJ, Fong G-H, Puri MC, Gradwohl G, et al. 1995. Vascularization of the mouse embryo:a study of flk-1, tek, tie, and vascular endothelial growth factor expression during development. Dev Dyn 203: 80-92.
17. Durando M, Kass L, Perdomo V, et al. 2011. Prenatal exposure to bisphenol A promotes angiogenesis and alters steroid-mediated responses in the mammary glands of cycling rats. J Steroid Bioch Mol Biol 127: 35-43.
18. Ema M, Iseb R, Katoc H, Onedad S, Hirosea A, et al. 2010. Fetal malformations and early embryonic gene expression response in cynomolgus monkeys maternally exposed to thalidomide. Reprod Toxicol 29: 49-56.
19. Eshkar-Oren I, Viukov SV, Salameh S, et al. 2009. The forming limb skeleton serves as a signaling center for limb vasculature patterning via regulation of Vegf. Development 136: 1263-1272.
20. Fantin A, Vieira JM, Gestri G, et al. 2010. Tissue macrophages act as cellular chaperones for vascular anastomosis downstream of VEGF-mediated endothelial tip cell induction. Blood 116: 829-840.
21. Furuyama T, Kitayama K, Shimoda Y, et al. 2004. Abnormal angiogenesis in Foxo1 (Fkhr)-deficient mice. J Biol Chem 279: 34741-34749.
22. Gaengel K, Genové G, Armulik A, Betsholtz C. 2009. Endothelial-mural cell signaling in vascular development and angiogenesis. Arterioscler Thromb Vasc Biol 29: 630-638.
23. Gagliardi A, Collins DC. 1993. Inhibition of angiogenesis by antiestrogens. Cancer Res 5: 533-535.
24. Hanahan D. 1997. Signaling vascular morphogenesis and maintenance. Science 277: 48-50.
25. Hartung T. 2009. Toxicology for the twenty-first century. Nature 460: 208-212.
26. Herbert SP and Stainier DYR. 2011. Molecular control of endothelial cell behaviour during blood vessel Morphogenesis. Nat Rev Mol Cell Biol 12: 551-564.
27. Hiratsuka S, Nakao K, Nakamura K, et al. 2005. Membrane fixation of vascular endothelial growth factor receptor 1 ligand-binding domain is important for vasculogenesis and angiogenesis in mice. Mol Cell Biol 25: 346-354.
28. Hurtt ME, Cappon GD, Browning A. 2003. Proposal for a tiered approach to developmental toxicity testing for veterinary pharmaceutical products for food producing animals. Food Chem Toxicol 41: 611-619.
29. Ishimura R, Kawakami T, Ohsako S, et al. 2006. Suppressive effect of 2, 3, 7, 8-Tetrachlorodibenzo-p-dioxin on vascular remodeling that takes place in the normal labyrinth zone of rat placenta during late gestation. Toxicol Sci 91: 265-274.
30. Ito T, Ando H, Suzuki T, et al. 2010. Identification of a primary target of thalidomide teratogenicity. Science 327: 1345-1350.
31. Judson R, Houck KA, Kavlock RJ, et al. 2010. In vitro screening of environmental chemicals for targeted testing prioritization - the ToxCast project. Environ Health Perspect 118: 485-492.
32. Kajio F, Nakazawa M, 1997. Vascular effects of endothelin-1 in stage 21 chick embryos. Heart Vessel 12: 300-305.
33. Kappas NC, Zeng G, Chappell JC, et al. 2008. The VEGF receptor Flt-1 spatially modulates Flk-1 signaling and blood vessel branching. J Cell Biol 181: 847-858.
34. Keeley EC, Mehrad B, Strieter RM. 2008. Chemokines as mediators of neovascularization. Arterioscler Thromb Vasc Biol 28: 1928-1936.
35. Kimmel CA, Kimmel GL, Euling SY. 2006. Developmental and reproductive toxicity risk assessment for environmental agents. In: Hood RD, editor, Developmental and reproductive toxicology, a practical approach. Boca Raton, FL: CRC Press.
36. Kitambi SS, MaCulloch KJ, Peterson RT, Malicki JJ. 2009. Small molecule screen for compounds that affect vascular development in the zebrafish retina. Mech Dev 126: 464-477.
37. Kleinstreuer NC, Judson RS, Reif DM, et al. 2011. Environmental impact on vascular development predicted by high-throughput screening. Environ Health Perspect 119: 1596-1603.
38. Knudsen TB, Martin MT, Kavlock RJ, et al. 2009. Profiling the activity of environmental chemicals in prenatal developmental toxicity studies using the U.S. EPA's ToxRefDB. Reprod Toxicol 28: 209-219.
39. Knudsen TB, Kavlock RJ, Daston GP, et al. 2011. Developmental toxicity testing for safety assessment: New approaches and technologies. Birth Defects Res B 92: 413-420.
40. Kuhnert F, Mancuso MR, Shamloo A, et al. 2010. Essential regulation of CNS angiogenesis by the orphan G protein-coupled receptor GPR124. Science 330: 985-989.
41. Le Noble F, Fleury V, Pries A, et al. 2005. Control of arterial branching morphogenesis in embryogenesis:go with the flow. Cardiovasc Res 65: 61-28.
42. Lebrin F, Srun S, Raymon K, et al. 2010. Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia. Nat Med 16: 420-428.
43. Long X, Burke KA, Bigsby RM, Nephew KP. 2001. Effects of the xenoestrogen bisphenol A on expression of vascular endothelial growth factor (VEGF) in the rat. Exp Biol Med 226: 477-483.
44. Lucitti JL, Jones EAV, Huang C, et al. 2007. Vascular remodeling of the mouse yolk sac requires hemodynamic force. Development 134: 3317-3326.
45. McCollum CW, Ducharme NA, Bondesson M, Gustafsson J-A. 2011. Developmental toxicity screening in zebrafish. Birth Defects Res C 93: 67-114.
46. Maltepe E and Celeste Simon M. 1998. Oxygen, genes, and development:An analysis of the role of hypoxic gene regulation during murine vascular development. J Mol Med 76: 391-401.
47. Martin MT, Judson RS, Reif DM, et al. 2009a. Profiling chemicals based on chronic toxicity results from the U.S. EPA ToxRef database. Environ Health Perspect 117: 392-399.
48. Martin MT, Knudsen TB, Reif DM, et al. 2011. Predictive model of rat reproductive toxicity from ToxCast high-throughput screening. Biol Reprod 85: 327-339.
49. Martin MT, Mendez E, Corum DG, et al. 2009b. Profiling the reproductive toxicity of chemicals from multigeneration studies in the toxicity reference database. Toxicol Sci 110: 181-190.
50. May SR, Stewart NJ, Chang W and Peterson AS. 2004. A Titin mutation defines roles for circulation in endothelial morphogenesis. Dev Biol 270: 31-46.
51. Melkonian G, Cheung L, Marr R, et al. 2002. Mainstream and sidestream cigarette smoke inhibit growth and angiogenesis in the day 5 chick chorioallantoic membrane. Toxicol Sci 68: 237-248.
52. Mueller MD, Vigne JL, Minchenko A, et al. 2000. Regulation of vascular endothelial growth factor (VEGF) gene transcription by estrogen receptors alpha and beta. Proc Natl Acad Sci U S A 97: 10972-10977.
53. Melkonian G, Eckelhoefer H, Wu M, et al. 2003. Growth and angiogenesis are inhibited in vivo in developing tissues by pyrazine and its derivatives. Toxicol Sci 74: 393-401.
54. National Research Council. 2007. Toxicity testing in the 21st century: A vision and a strategy. The National Academies Press, Washington, DC.
55. Ng SSW, Gütschow M, Weiss M, et al. 2003. Antiangiogenic Activity of N-substituted and tetrafluorinated thalidomide analogues. Cancer Res 63: 3189-3194.
56. Noguchi T, Fujimoto H, Sano H, et al. 2005. Angiogenesis inhibitors derived from thalidomide. Bioorg Med Chem Lett 15: 5509-5513.
57. Potente M, Gerhardt H, Carmeliet P. Basic and therapeutic aspects of angiogenesis. Cell 0000 146: 873-887.
58. Pudliszewski M and Pardanaud L. 2005. Vasculogenesis and angiogenesis in the mouse embryo studied using quail/mouse chimeras. Int J Dev Biol 49: 355-361.
59. Reif D, Martin M, Tan S, et al. (2010) Endocrine Profiling and Prioritization of Environmental Chemicals Using ToxCast Data. Environ Hlth Persp 118: 1714-1720.
60. Rogers JM and Abbott BD. 2003. Screening for developmental toxicity of tobacco smoke constituents. Toxicol Sci 75: 227-228.
61. Sarkanen J-R, Mannerström M, Vuorenpää H, et al. 2011. Intra-laboratory pre-validation of a human cell based in vitro angiogenesis assay for testing angiogenesis modulators. Front Pharmacol 1: 1-13.
62. Sauer H, Günther J, Hescheler J, Wartenberg M. 2000. Thalidomide inhibits angiogenesis in embryoid bodies by the generation of hydroxyl radicals. Am J Pathol 156: 151-158.
63. Semenza GL. 2006. Regulation of physiological responses to continuous and intermittent hypoxia by hypoxia-inducible factor. Exp Physiol 91: 803-806.
64. Shah I, Houck K, Judson RS, et al. 2011. Using nuclear receptor activity to stratify hepatocarcinogens. PLoS One 6: e14584.
65. Sipes NS, Martin MT, Reif DM, et al. 2011. Predictive models of prenatal developmental toxicity from ToxCast high throughput screening data. Toxicol Sci 124: 109-127.
66. Spence S, Anderson C, Cukierski M, Patrick D. 1999. Teratogenic effects of the endothelin receptor antagonist L-753, 037 in the rat. Reprod Toxicol 13: 15-29.
67. Stenman JM, Rajagopal J, Carroll TJ, Ishibashi M, et al. 2008. Canonical Wnt signaling regulates organ-specific assembly and differentiation of CNS vasculature. Science 322: 1247-1250.
68. Stephens TD, Bunde CJ, Fillmore BJ. 2000. Mechanism of action in thalidomide teratogenesis. Biochem Pharmacol 59: 1489-1499.
69. Suzuki Y, Komi Y, Ashino H, et al. 2004. Retinoic acid controls blood vessel formation by modulating endothelial and mural cell interaction via suppression of Tie2 signaling in vascular progenitor cells. Blood 104: 166-169.
70. Therapontos C, Erskine L, Gardner ER, et al. 2009. Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation. Proc Natl Acad Sci U S A 109: 8573-8578.
71. Treinen K, Louden C, Dennis M, and Wier P. 1999. Developmental toxicity and toxicokinetics of two endothelin receptor antagonists in rats and rabbits. Teratology 59: 51-59.
72. van Hinsbergh VWM, Engelse MA, and Quax PHA. 2006. Pericellular proteases in angiogenesis and vasculogenesis. Arterioscler Thromb Vasc Biol 26: 716-728.
73. Vargesson N. 2009. Thalidomide-induced limb defects:resolving a 50-year-old puzzle. BioEssays 31: 1327-1336.
74. Walls JR, Coultas L, Rossant J, Henkelman RM. 2008. Three-dimensional analysis of vascular development in the mouse embryo. PLoS ONE 3: e2853.
75. Xia M, Bi K, Cho MH, et al. 2009. Identification of small molecule compounds that inhibit the HIF-1 signaling pathway. Mol Cancer 8: 117.
76. Yabu T, Okazaki T, Tomimoto H, et al. 2005. Thalidomide-induced antiangiogenic action is mediated by ceramide through depletion of VEGF receptors, and is antagonized by sphingosine-1-phosphate. Blood 106: 125-134.
77. Yang SJ, Uriu-Adams JY, Keen CL, et al. 2006. Effects of copper deficiency on mouse yolk sac vasculature and expression of angiogenic mediators. Birth Defects Res B 77:445-454.